Logo

SNY

Sanofi

SNY

Sanofi • NASDAQ
$49.85 ▼ -0.36% (-0.18)
Market Cap $122.70 B
52w High $60.12
52w Low $44.62
Dividend Yield 2.21%
P/E 16.51
Volume 1.19M
Outstanding Shares 2.46B

Income Statement

Period Revenue Operating Expense Net Income Net Profit Margin Earnings Per Share EBITDA
Q3-2025 $13.17B ▲ $6.135B ▼ $2.802B ▼ 21.276% ▼ $1.15 ▼ $4.214B ▲
Q2-2025 $10.735B ▲ $6.269B ▲ $3.94B ▲ 36.702% ▲ $1.6 ▲ $1.889B ▼
Q1-2025 $10.606B ▲ $5.432B ▲ $1.872B ▲ 17.65% ▲ $0.76 ▲ $2.77B ▲
Q4-2024 $7.631B ▼ $4.787B ▼ $499M ▼ 6.539% ▼ $0.35 ▼ $563M ▼
Q3-2024 $14.157B $6.437B $2.815B 19.884% $1.13 $4.247B

Balance Statement

Period Cash & Short-term Total Assets Total Liabilities Total Equity
Q3-2025 $8.906B ▼ $129.794B ▲ $56.261B ▲ $73.263B ▲
Q2-2025 $15.359B ▲ $124.959B ▼ $54.68B ▼ $70.008B ▼
Q1-2025 $7.991B ▲ $131.892B ▼ $57.474B ▲ $74.074B ▼
Q4-2024 $7.927B ▲ $132.798B ▲ $54.941B ▲ $77.507B ▲
Q3-2024 $6.795B $0 $-72.997B $72.997B

Cash Flow Statement

Period Net Income Cash From Operations Cash From Investing Cash From Financing Net Change Free Cash Flow
Q2-2025 $3.94B ▲ $0 ▼ $0 ▲ $0 ▲ $0 ▼ $0 ▼
Q1-2025 $0 ▼ $2.093B ▲ $-776M ▼ $-592M ▼ $550M ▲ $2.093B ▲
Q4-2024 $683M ▼ $0 $0 $0 $0 $0
Q3-2024 $2.815B ▲ $0 ▼ $0 ▲ $0 ▼ $0 ▲ $0 ▲
Q2-2024 $1.113B $1.423B $-3.413B $89M $-1.915B $-504M

Five-Year Company Overview

Income Statement

Income Statement Revenue has grown steadily over the last several years, showing that Sanofi’s core businesses are expanding rather than shrinking. Profitability is solid but has been more up‑and‑down than sales, with some very strong years followed by more average ones, likely reflecting patent cycles, product mix, and one‑off items. Margins remain healthy for a large pharma company, but they do not move in a straight line, which is typical in this industry. Overall, the income statement suggests a mature, diversified drug maker with dependable revenue and profits that can fluctuate depending on product launches and lifecycle events.

Balance Sheet

Balance Sheet Sanofi’s asset base and shareholder equity have been gradually increasing, pointing to a business that is slowly but steadily building its financial foundation. Debt has been edging down over time, which reduces financial risk and interest burden. Cash levels move around from year to year but remain comfortably positive, giving the company room to invest and handle shocks. In short, the balance sheet looks sturdy, with a moderate use of debt and a clear trend toward a stronger equity position.

Cash Flow

Cash Flow Cash generation from day‑to‑day operations is strong and has generally improved compared with earlier years, which is a good sign of the underlying health of the business. Free cash flow is solidly positive, even after investment spending, indicating Sanofi typically generates more cash than it consumes. Capital spending has ticked up recently, likely reflecting heavier investment in manufacturing, labs, and new platforms to support the innovation push. Overall, the cash flow profile looks resilient and supportive of continued R&D, strategic deals, and shareholder returns, though increased investment can put some short‑term pressure on reported free cash flow.

Competitive Edge

Competitive Edge Sanofi is a large global pharma player with strength across several areas: vaccines, immunology, general medicines, and rare diseases. Its breadth of products and worldwide footprint help smooth out the impact of any single drug losing exclusivity, which is a key advantage in this industry. The company enjoys strong positions in vaccines and in certain specialty areas, and its scale gives it cost and distribution benefits smaller rivals lack. At the same time, Sanofi faces intense competition from other major drug makers, ongoing pricing pressure from payers and governments, and the constant need to replace aging products with new ones to maintain its market standing.

Innovation and R&D

Innovation and R&D Sanofi is clearly leaning into an innovation‑heavy future, repositioning itself as a focused biopharma company and spinning off consumer health. Its R&D strategy is centered on high‑value areas like immunology, vaccines, oncology, and rare diseases, with a particularly powerful growth engine in Dupixent and a deep late‑stage pipeline. The company is investing in modern technologies such as AI‑driven discovery, mRNA platforms, and advanced antibody engineering, and is using targeted acquisitions to fill gaps and speed up its pipeline. This shift raises execution risks—clinical failures, regulatory setbacks, and higher R&D spend can all weigh on near‑term results—but, if successful, it could meaningfully reshape Sanofi’s growth and margin profile over the next decade.

Summary

Sanofi looks like a financially solid, globally diversified pharma company that is moving through a strategic transformation. Its revenue base is growing steadily, supported by strong franchises and a wide product mix, while profits remain healthy but naturally choppy given industry dynamics. The balance sheet and cash flows appear robust enough to support elevated investment in R&D and strategic deals without overstretching the company. Strategically, Sanofi is doubling down on innovation in immunology, vaccines, and specialty areas, with a sizeable late‑stage pipeline but also the usual execution and regulatory risks that come with an R&D‑driven model. Overall, the company is trading some near‑term simplicity for a more focused, innovation‑centric profile that could significantly influence its long‑term trajectory, positively or negatively, depending on how well the pipeline delivers.

NEWS

November 25, 2025 · 1:00 AM UTC

Press Release: Sanofi and Regeneron's Dupixent approved as the first targeted medicine in the EU in over a decade for chronic spontaneous urticaria

Read more

November 18, 2025 · 12:20 PM UTC

Lifordi Immunotherapeutics Secures Strategic Investment from Sanofi Ventures and Additional Capital from Existing Investors

Read more

November 18, 2025 · 12:00 PM UTC

Lifordi Immunotherapeutics Secures Strategic Investment from Sanofi Ventures and Additional Capital from Existing Investors

Read more

November 14, 2025 · 6:30 AM UTC

Press Release: Sanofi's Teizeild recommended for EU approval by the CHMP for patients with stage 2 type 1 diabetes

Read more

November 7, 2025 · 8:00 AM UTC

Press Release: ACAAI: Sanofi and Regeneron's Dupixent pivotal study met all primary and secondary endpoints, reducing signs and symptoms of allergic fungal rhinosinusitis; sBLA accepted for FDA priority review

Read more